NCT04495101View on ClinicalTrials.gov

Study to Evaluate the Safety and Efficacy of Prolastin in Hospitalized Subjects With COVID-19

PHASE2CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

July 29, 2020

Primary Completion Date

April 26, 2021

Study Completion Date

June 10, 2021

Conditions
COVID-19
Interventions
BIOLOGICAL

Prolastin

Intravenous infusion 120 mg/kg

DRUG

Standard Medical Treatment

Standard medical treatment per local policies or guidelines

Trial Locations (9)

09006

Hospital Universitario de Burgos, Burgos

Unknown

Hospital Universitari Germans Trias i Pujol, Badalona

Hospital Clínic de Barcelona, Barcelona

Hospital Universitario Valle de Hebrón, Barcelona

Hospital Clínico San Carlos, Madrid

Hospital General Gregorio Marañón, Madrid

Hospital Universitario Infanta Leonor, Madrid

Hospital Universitario Príncipe de Asturias, Madrid

Hospital Universitario Ramón y Cajal, Madrid

All Listed Sponsors
lead

Instituto Grifols, S.A.

INDUSTRY

NCT04495101 - Study to Evaluate the Safety and Efficacy of Prolastin in Hospitalized Subjects With COVID-19 | Biotech Hunter | Biotech Hunter